首页 > 最新文献

Journal of Clinical Research in Pediatric Endocrinology最新文献

英文 中文
Iodinated Contrast Induced Hypothyroidism in the Infant After Enteral Contrast Enema: A Case Report and Systematic Review. 婴儿经肠内对比剂灌肠后碘化对比剂诱发的甲状腺功能减退症:病例报告与系统回顾
IF 1.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-28 DOI: 10.4274/jcrpe.galenos.2024.2023-12-2
Adinda G H Pijpers, Sandra E Zoetelief, Laurens D Eeftinck Schattenkerk, Ralph de Vries, Wes Onland, Joost van Schuppen, A S Paul van Trotsenburg, L W Ernest van Heurn, Joep P M Derikx, Nitash Zwaveling-Soonawala, Christiaan F Mooij

Background: Excessive iodine intake triggers the Wolff-Chaikoff effect resulting in downregulation of thyroid hormone synthesis to prevent hyperthyroidism. Failure to escape the Wolff-Chaikoff effect can be seen especially in (premature born) infants and may result in prolonged iodine induced hypothyroidism. We describe a rare case of a preterm infant who developed severe iodinated contrast induced hypothyroidism after the use and prolonged stasis of enteral iodinated contrast media (ICM). In addition a systematic literature search was performed to evaluate all available data on this complication.

Methods: A systematic literature search was performed in PubMed and Embase. Studies describing the effect of enteral ICM on thyroid function were considered eligible. The primary outcome was to determine the frequency of contrast induced hypothyroidism in infants after administration of enteral ICM.

Results: The premature infant in our center developed severe iodinated contrast induced hypothyroidism after enteral ICM. In total, only two studies met our eligibility data, reporting eight patients. Out of these eight patients, four premature infants developed a contrast induced hypothyroidism after enteral administration of ICM.

Conclusion: Data on severity, length and frequency of contrast induced hypothyroidism after exposure to enteral ICM is very scarce. The herein reported case and literature search illustrate the potential severity of the complication and underline the necessity of future studies on this topic. We recommend standardized monitoring of thyroid function after exposure to enteral ICM in newborns to prevent delayed diagnosis of severe contrast induced hypothyroidism until evidence based recommendations can be made.

背景:碘摄入过量会引发沃尔夫-柴可夫效应,导致甲状腺激素合成下调,从而预防甲状腺功能亢进。未能摆脱沃尔夫-柴可夫效应的情况在(早产)婴儿中尤为常见,并可能导致长期的碘诱发甲状腺功能减退症。我们描述了一例罕见的早产儿病例,该患者在使用并长期滞留肠道碘造影剂(ICM)后出现了严重的碘造影剂诱导的甲状腺功能减退症。此外,我们还进行了系统性文献检索,以评估有关该并发症的所有可用数据:在 PubMed 和 Embase 中进行了系统性文献检索。描述肠道 ICM 对甲状腺功能影响的研究均符合条件。主要结果是确定婴儿服用肠道 ICM 后出现对比剂诱发甲状腺功能减退的频率:我们中心的早产儿在服用肠道 ICM 后出现了严重的碘造影剂诱发甲状腺功能减退症。总共只有两项研究符合我们的资格数据,报告了 8 名患者。在这 8 名患者中,有 4 名早产儿在肠道给药 ICM 后出现了造影剂诱发的甲状腺功能减退症:结论:有关肠道输入 ICM 后造影剂诱发甲状腺功能减退症的严重程度、持续时间和频率的数据非常稀少。本文报告的病例和文献检索说明了该并发症的潜在严重性,并强调了今后对该主题进行研究的必要性。我们建议对新生儿暴露于肠内 ICM 后的甲状腺功能进行标准化监测,以防止严重造影剂诱导的甲状腺功能减退症被延迟诊断,直到可以提出基于证据的建议。
{"title":"Iodinated Contrast Induced Hypothyroidism in the Infant After Enteral Contrast Enema: A Case Report and Systematic Review.","authors":"Adinda G H Pijpers, Sandra E Zoetelief, Laurens D Eeftinck Schattenkerk, Ralph de Vries, Wes Onland, Joost van Schuppen, A S Paul van Trotsenburg, L W Ernest van Heurn, Joep P M Derikx, Nitash Zwaveling-Soonawala, Christiaan F Mooij","doi":"10.4274/jcrpe.galenos.2024.2023-12-2","DOIUrl":"https://doi.org/10.4274/jcrpe.galenos.2024.2023-12-2","url":null,"abstract":"<p><strong>Background: </strong>Excessive iodine intake triggers the Wolff-Chaikoff effect resulting in downregulation of thyroid hormone synthesis to prevent hyperthyroidism. Failure to escape the Wolff-Chaikoff effect can be seen especially in (premature born) infants and may result in prolonged iodine induced hypothyroidism. We describe a rare case of a preterm infant who developed severe iodinated contrast induced hypothyroidism after the use and prolonged stasis of enteral iodinated contrast media (ICM). In addition a systematic literature search was performed to evaluate all available data on this complication.</p><p><strong>Methods: </strong>A systematic literature search was performed in PubMed and Embase. Studies describing the effect of enteral ICM on thyroid function were considered eligible. The primary outcome was to determine the frequency of contrast induced hypothyroidism in infants after administration of enteral ICM.</p><p><strong>Results: </strong>The premature infant in our center developed severe iodinated contrast induced hypothyroidism after enteral ICM. In total, only two studies met our eligibility data, reporting eight patients. Out of these eight patients, four premature infants developed a contrast induced hypothyroidism after enteral administration of ICM.</p><p><strong>Conclusion: </strong>Data on severity, length and frequency of contrast induced hypothyroidism after exposure to enteral ICM is very scarce. The herein reported case and literature search illustrate the potential severity of the complication and underline the necessity of future studies on this topic. We recommend standardized monitoring of thyroid function after exposure to enteral ICM in newborns to prevent delayed diagnosis of severe contrast induced hypothyroidism until evidence based recommendations can be made.</p>","PeriodicalId":48805,"journal":{"name":"Journal of Clinical Research in Pediatric Endocrinology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding the Clinical Features of Schimke Immuno-Osseous Dysplasia: A New Patient with a Novel Variant and Novel Clinical Findings. 扩展希姆克免疫骨发育不良症的临床特征:一名新变异患者和新临床发现。
IF 1.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-08 DOI: 10.4274/jcrpe.galenos.2024.2024-1-17
Ceren Alavanda, Şenol Demir, Serçin Güven, Mehmet Eltan, Sevgi Bilgiç Eltan, Asena Pınar Sefer, Serim Pul, Tülay Güran, Harika Alpay, Ahmet Arman, Pınar Ata, Serap Turan

Schimke Immuno-Osseous Dysplasia (SIOD) (MIM:242900) is an ultra-rare autosomal recessive pan-ethnic pleiotropic disease. Typical findings of this syndrome are steroid-resistant nephrotic syndrome, cellular immunodeficiency and spondyloepiphyseal dysplasia and facial dysmorphism. Biallelic variants in the SMARCAL1 gene cause SIOD. The five-and-half-year-old female patient was evaluated because of short stature, dysmorphism, hypercalcemia, hypophosphatemia and elevated FSH levels. Karyotype analysis and array-CGH testing were normal. Clinical Exome Sequencing was performed via next-generation sequencing to analyze genes associated with hypophosphatemia. No pathogenic variant was detected. The subsequent detection of proteinuria during her follow-up for cross-fused ectopic left kidney ultimately facilitated the diagnosis of SIOD, although no obvious spondyloepiphyseal dysplasia was detected. Re-analysis of CES revealed a novel homozygous c.2422_2427+9delinsA pathogenic variant in the SMARCAL1. One hundred twenty-five SIOD cases from 38 literature reporting SMARCAL1 gene pathogenic variants were reviewed to investigate whether hypercalcemia, hypophosphatemia and elevated FSH levels had been previously reported in SIOD patients. This review revealed that this was the first time these findings had been reported in a SIOD patient. This report expands not only the phenotypic but also genotypic spectrum of SIOD.

施麦克免疫骨发育不良症(SIOD)(MIM:242900)是一种超罕见的常染色体隐性泛种族多型性疾病。该综合征的典型表现是类固醇抵抗性肾病综合征、细胞免疫缺陷、脊柱骺发育不良和面部畸形。SMARCAL1 基因的双倍变体可导致 SIOD。这名五岁半的女性患者因身材矮小、畸形、高钙血症、低磷血症和 FSH 水平升高而接受评估。核型分析和阵列-CGH检测均正常。通过新一代测序技术进行了临床外显子组测序,以分析与低磷血症相关的基因。未检测到致病变体。虽然没有发现明显的脊柱骺发育不良,但随后在对交叉融合的异位左肾进行随访时发现了蛋白尿,最终帮助确诊为 SIOD。对 CES 的再次分析发现,SMARCAL1 中存在一个新的同基因 c.2422_2427+9delinsA 致病变异。研究人员回顾了38篇报道SMARCAL1基因致病变异的文献中的125例SIOD病例,以调查SIOD患者是否曾出现高钙血症、低磷血症和FSH水平升高。审查结果显示,这是首次在 SIOD 患者中报告这些结果。该报告不仅扩展了 SIOD 的表型谱,也扩展了其基因型谱。
{"title":"Expanding the Clinical Features of Schimke Immuno-Osseous Dysplasia: A New Patient with a Novel Variant and Novel Clinical Findings.","authors":"Ceren Alavanda, Şenol Demir, Serçin Güven, Mehmet Eltan, Sevgi Bilgiç Eltan, Asena Pınar Sefer, Serim Pul, Tülay Güran, Harika Alpay, Ahmet Arman, Pınar Ata, Serap Turan","doi":"10.4274/jcrpe.galenos.2024.2024-1-17","DOIUrl":"https://doi.org/10.4274/jcrpe.galenos.2024.2024-1-17","url":null,"abstract":"<p><p>Schimke Immuno-Osseous Dysplasia (SIOD) (MIM:242900) is an ultra-rare autosomal recessive pan-ethnic pleiotropic disease. Typical findings of this syndrome are steroid-resistant nephrotic syndrome, cellular immunodeficiency and spondyloepiphyseal dysplasia and facial dysmorphism. Biallelic variants in the <i>SMARCAL1</i> gene cause SIOD. The five-and-half-year-old female patient was evaluated because of short stature, dysmorphism, hypercalcemia, hypophosphatemia and elevated FSH levels. Karyotype analysis and array-CGH testing were normal. Clinical Exome Sequencing was performed via next-generation sequencing to analyze genes associated with hypophosphatemia. No pathogenic variant was detected. The subsequent detection of proteinuria during her follow-up for cross-fused ectopic left kidney ultimately facilitated the diagnosis of SIOD, although no obvious spondyloepiphyseal dysplasia was detected. Re-analysis of CES revealed a novel homozygous c.2422_2427+9delinsA pathogenic variant in the <i>SMARCAL1</i>. One hundred twenty-five SIOD cases from 38 literature reporting <i>SMARCAL1</i> gene pathogenic variants were reviewed to investigate whether hypercalcemia, hypophosphatemia and elevated FSH levels had been previously reported in SIOD patients. This review revealed that this was the first time these findings had been reported in a SIOD patient. This report expands not only the phenotypic but also genotypic spectrum of SIOD.</p>","PeriodicalId":48805,"journal":{"name":"Journal of Clinical Research in Pediatric Endocrinology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hospital Admission for Diabetic Ketoacidosis in Thai Children and Adolescents with Type 1 Diabetes: A National Study during 2015-2019. 泰国儿童和青少年 1 型糖尿病患者因糖尿病酮症酸中毒入院情况:2015-2019 年期间的一项全国性研究。
IF 1.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-08 DOI: 10.4274/jcrpe.galenos.2024.2024-6-4
Somboon Wankanit, Kaewjai Thepsuthammarat, Preamrudee Poomthavorn, Taninee Sahakitrungruang, Pat Mahachoklertwattana

Objective: To study the national incidence of admission for diabetic ketoacidosis (DKA) in Thai children and adolescents with type 1 diabetes (T1D) and characterize risk factors for DKA admission.

Methods: Admission records of children and adolescents with T1D during the years 2015-2019 were retrieved from the Thai health coverage system of all schemes. Hospitalization was categorized according to patients' age groups (<1, 1-5, 6-12 and 13-17 years), sex and geographical regions (Bangkok, Central, Northeast, North and South). DKA admission incidence and rate were calculated and compared among subgroups.

Results: The annual incidences of T1D and DKA admissions progressively increased over the study period (T1D: 12.0 to 15.0, p<0.001 and DKA: 4.8 to 7.3 per 100,000 child-years, p<0.001). About half of DKA admissions (52%) were recurrent episodes. DKA admission rate was 1.49 admissions/patient. The incidence of DKA admission was greatest in individuals aged 13-17 years (13-17 years: 10.3; 6-12 years: 6.3; 1-5 years: 1.7; and <1 year: 0.6 per 100,000 child-years, p<0.001). DKA admission incidence was greater in females than males (7.6 vs. 4.3 per 100,000 child-years, p<0.001). Among 5 geographical regions, greatest percentage of recurrent DKA (57%), rate of increased annual incidence of DKA admission (3.8 to 7.8 per 100,000 child-years), and DKA admission rate (1.64 admissions/patient) were found in the Northeast region.

Conclusions: During the years 2015-2019, rising annual incidences of T1D and DKA admissions among Thai youth were observed. Individuals older than 6 years, being females, and resided in the Northeast region had higher risk for DKA hospitalization.

目的研究泰国1型糖尿病(T1D)儿童和青少年因糖尿病酮症酸中毒(DKA)入院的全国发病率,并分析DKA入院的风险因素:从泰国医疗保险系统的所有计划中检索了 2015-2019 年期间患有 T1D 的儿童和青少年的入院记录。根据患者的年龄组对住院情况进行分类(结果:T1D和T1D患者的年发病率分别为1.5%和1.5%:在研究期间,T1D 和 DKA 住院的年发病率逐渐增加(T1D:12.0 至 15.0,P 结论:在 2015-2019 年期间,T1D 和 DKA 住院的年发病率逐渐增加:2015-2019年期间,泰国青少年的T1D和DKA年发病率不断上升。年龄大于6岁、女性和居住在东北部地区的人有更高的DKA住院风险。
{"title":"Hospital Admission for Diabetic Ketoacidosis in Thai Children and Adolescents with Type 1 Diabetes: A National Study during 2015-2019.","authors":"Somboon Wankanit, Kaewjai Thepsuthammarat, Preamrudee Poomthavorn, Taninee Sahakitrungruang, Pat Mahachoklertwattana","doi":"10.4274/jcrpe.galenos.2024.2024-6-4","DOIUrl":"https://doi.org/10.4274/jcrpe.galenos.2024.2024-6-4","url":null,"abstract":"<p><strong>Objective: </strong>To study the national incidence of admission for diabetic ketoacidosis (DKA) in Thai children and adolescents with type 1 diabetes (T1D) and characterize risk factors for DKA admission.</p><p><strong>Methods: </strong>Admission records of children and adolescents with T1D during the years 2015-2019 were retrieved from the Thai health coverage system of all schemes. Hospitalization was categorized according to patients' age groups (<1, 1-5, 6-12 and 13-17 years), sex and geographical regions (Bangkok, Central, Northeast, North and South). DKA admission incidence and rate were calculated and compared among subgroups.</p><p><strong>Results: </strong>The annual incidences of T1D and DKA admissions progressively increased over the study period (T1D: 12.0 to 15.0, p<0.001 and DKA: 4.8 to 7.3 per 100,000 child-years, p<0.001). About half of DKA admissions (52%) were recurrent episodes. DKA admission rate was 1.49 admissions/patient. The incidence of DKA admission was greatest in individuals aged 13-17 years (13-17 years: 10.3; 6-12 years: 6.3; 1-5 years: 1.7; and <1 year: 0.6 per 100,000 child-years, p<0.001). DKA admission incidence was greater in females than males (7.6 vs. 4.3 per 100,000 child-years, p<0.001). Among 5 geographical regions, greatest percentage of recurrent DKA (57%), rate of increased annual incidence of DKA admission (3.8 to 7.8 per 100,000 child-years), and DKA admission rate (1.64 admissions/patient) were found in the Northeast region.</p><p><strong>Conclusions: </strong>During the years 2015-2019, rising annual incidences of T1D and DKA admissions among Thai youth were observed. Individuals older than 6 years, being females, and resided in the Northeast region had higher risk for DKA hospitalization.</p>","PeriodicalId":48805,"journal":{"name":"Journal of Clinical Research in Pediatric Endocrinology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endocrine Disorders in Children with Primary Mitochondrial Diseases: Single-Center Experience. 原发性线粒体疾病儿童的内分泌失调:单中心经验。
IF 1.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-08 DOI: 10.4274/jcrpe.galenos.2024.2024-1-11
Esra Deniz Papatya Çakır, Melike Ersıoy, Nihan Çakır Biçer, Asuman Gedikbaşı

Objective: Endocrine abnormalities may represent the only clinical manifestation of primary mitochondrial disorders. This study aimed to evaluate the endocrinological characteristics of mitochondrial disease in our cohort.

Methods: A total of twenty-six pediatric patients diagnosed with mitochondrial disease were categorized on the basis of their specific genetic abnormalities. The auxologic data, pubertal development, and, based on their clinical symptoms, hormonal profiles were obtained.

Results: Twelve of the cohort of 26 patients (46%) were female. In 15 of the patients (57.6%), their mitochondrial disease (MD) was caused by nuclear DNA mutations (nDNA group). Four patients had Leigh syndrome, 2 patients had LHON syndrome, 2 patients had MELAS, and 1 patient had KSS clinical phenotype. The median age at diagnosis was 2.91 (0.59-16.8) years, and the median age at first endocrinologic evaluation was 4.62 (1.26-18) years. The mean height SDS was -1.34 ± 2.12, and the mean BMI SDS was -0.82 ± 1.96 for all patients. Of the 26 patients, 6 (23%) had a range of hormonal deficits. Ovarian insufficiency, central adrenal insufficiency, central hypothyroidism, diabetes mellitus, and critical illness-related adrenal insufficiency were all observed. Three of the patients were initially monitored in the endocrine clinic for hormone deficiencies but it was later determined that the hormonal abnormalities were caused by underlying mitochondrial disease.

Conclusion: Individuals diagnosed with mitochondrial disease, particularly those with specific genetic abnormalities, are considered a high-risk group for developing hormonal deficits. Endocrine diseases could be one of the primary mitochondrial disorders' early warning symptoms.

目的:内分泌异常可能是原发性线粒体疾病的唯一临床表现。本研究旨在评估我院队列中线粒体疾病的内分泌特征:方法:根据特定基因异常对 26 名确诊为线粒体疾病的儿科患者进行分类。方法:根据特定的基因异常对 26 名确诊为线粒体病的儿科患者进行分类,并获得辅助检查数据、青春期发育情况,以及根据临床症状得出的激素谱:结果:26 名患者中有 12 人(46%)为女性。其中 15 名患者(57.6%)的线粒体疾病(MD)是由核 DNA 变异(nDNA 组)引起的。4 名患者患有 Leigh 综合征,2 名患者患有 LHON 综合征,2 名患者患有 MELAS,1 名患者患有 KSS 临床表型。确诊时的中位年龄为2.91(0.59-16.8)岁,首次接受内分泌评估时的中位年龄为4.62(1.26-18)岁。所有患者的平均身高 SDS 为 -1.34 ± 2.12,平均体重指数 SDS 为 -0.82 ± 1.96。在 26 名患者中,有 6 人(23%)存在一系列激素缺陷。卵巢功能不全、中枢性肾上腺功能不全、中枢性甲状腺功能减退、糖尿病和与危重疾病相关的肾上腺功能不全。其中三名患者最初在内分泌诊所接受激素缺乏症监测,但后来确定激素异常是由潜在的线粒体疾病引起的:结论:被诊断出患有线粒体疾病的人,尤其是那些有特定基因异常的人,被认为是出现激素缺乏症的高危人群。内分泌疾病可能是线粒体疾病的主要预警症状之一。
{"title":"Endocrine Disorders in Children with Primary Mitochondrial Diseases: Single-Center Experience.","authors":"Esra Deniz Papatya Çakır, Melike Ersıoy, Nihan Çakır Biçer, Asuman Gedikbaşı","doi":"10.4274/jcrpe.galenos.2024.2024-1-11","DOIUrl":"https://doi.org/10.4274/jcrpe.galenos.2024.2024-1-11","url":null,"abstract":"<p><strong>Objective: </strong>Endocrine abnormalities may represent the only clinical manifestation of primary mitochondrial disorders. This study aimed to evaluate the endocrinological characteristics of mitochondrial disease in our cohort.</p><p><strong>Methods: </strong>A total of twenty-six pediatric patients diagnosed with mitochondrial disease were categorized on the basis of their specific genetic abnormalities. The auxologic data, pubertal development, and, based on their clinical symptoms, hormonal profiles were obtained.</p><p><strong>Results: </strong>Twelve of the cohort of 26 patients (46%) were female. In 15 of the patients (57.6%), their mitochondrial disease (MD) was caused by nuclear DNA mutations (nDNA group). Four patients had Leigh syndrome, 2 patients had LHON syndrome, 2 patients had MELAS, and 1 patient had KSS clinical phenotype. The median age at diagnosis was 2.91 (0.59-16.8) years, and the median age at first endocrinologic evaluation was 4.62 (1.26-18) years. The mean height SDS was -1.34 ± 2.12, and the mean BMI SDS was -0.82 ± 1.96 for all patients. Of the 26 patients, 6 (23%) had a range of hormonal deficits. Ovarian insufficiency, central adrenal insufficiency, central hypothyroidism, diabetes mellitus, and critical illness-related adrenal insufficiency were all observed. Three of the patients were initially monitored in the endocrine clinic for hormone deficiencies but it was later determined that the hormonal abnormalities were caused by underlying mitochondrial disease.</p><p><strong>Conclusion: </strong>Individuals diagnosed with mitochondrial disease, particularly those with specific genetic abnormalities, are considered a high-risk group for developing hormonal deficits. Endocrine diseases could be one of the primary mitochondrial disorders' early warning symptoms.</p>","PeriodicalId":48805,"journal":{"name":"Journal of Clinical Research in Pediatric Endocrinology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Making Teachers and School Health Nurses Part of Pediatric Diabetes Teams. 让教师和学校保健护士成为儿科糖尿病小组的一员。
IF 1.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-08 DOI: 10.4274/jcrpe.galenos.2024.2024-5-12
Şükrü Hatun, Gül Yeşiltepe Mutlu, Gülcan Kılınç, Zehra Aycan

Children with diabetes need consistent care across all environments, including school, where they spend significant time.Turkey's Diabetes at School Program, initiated in 2010, has made substantial progress in integrating diabetes care into the school system. The program's achievements include government support, annual awareness activities, communication between diabetes teams and schools, policy implementation, and training for school staff. A recent meeting of Provincial Health Service Officers highlighted ongoing efforts and future directions for the program, emphasizing the importance of continuous support for children with diabetes in educational settings. Key outcomes of this meeting include designated caregivers for children with diabetes at school, optional administration of insulin by trained staff, mandatory diabetes education for teachers, and health-conscious policies for school activities. The program's success is attributed to the collaborative efforts of teachers, healthcare professionals, and government officials. Ensuring robust support for children with diabetes in schools is vital for their well-being and academic success.

土耳其的 "学校糖尿病计划 "于 2010 年启动,在将糖尿病护理纳入学校系统方面取得了实质性进展。该计划的成果包括政府支持、年度宣传活动、糖尿病团队与学校之间的沟通、政策实施以及对学校员工的培训。最近召开的一次省级卫生服务官员会议强调了该计划正在进行的工作和未来的发展方向,强调了为教育环境中的糖尿病儿童提供持续支持的重要性。这次会议的主要成果包括为在校的糖尿病儿童指定护理人员、由受过培训的教职员工选择性地使用胰岛素、对教师进行强制性糖尿病教育以及制定注重健康的学校活动政策。该计划的成功归功于教师、医护人员和政府官员的共同努力。确保为在校的糖尿病患儿提供强有力的支持,对他们的健康和学业成功至关重要。
{"title":"Making Teachers and School Health Nurses Part of Pediatric Diabetes Teams.","authors":"Şükrü Hatun, Gül Yeşiltepe Mutlu, Gülcan Kılınç, Zehra Aycan","doi":"10.4274/jcrpe.galenos.2024.2024-5-12","DOIUrl":"https://doi.org/10.4274/jcrpe.galenos.2024.2024-5-12","url":null,"abstract":"<p><p>Children with diabetes need consistent care across all environments, including school, where they spend significant time.Turkey's Diabetes at School Program, initiated in 2010, has made substantial progress in integrating diabetes care into the school system. The program's achievements include government support, annual awareness activities, communication between diabetes teams and schools, policy implementation, and training for school staff. A recent meeting of Provincial Health Service Officers highlighted ongoing efforts and future directions for the program, emphasizing the importance of continuous support for children with diabetes in educational settings. Key outcomes of this meeting include designated caregivers for children with diabetes at school, optional administration of insulin by trained staff, mandatory diabetes education for teachers, and health-conscious policies for school activities. The program's success is attributed to the collaborative efforts of teachers, healthcare professionals, and government officials. Ensuring robust support for children with diabetes in schools is vital for their well-being and academic success.</p>","PeriodicalId":48805,"journal":{"name":"Journal of Clinical Research in Pediatric Endocrinology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experience in a PHTS Expertise Centre: Yield of Thyroid Ultrasound Surveillance in Children with PTEN Hamartoma Tumor Syndrome. PHTS专家中心的经验:PTEN Hamartoma肿瘤综合征患儿甲状腺超声监测的收益。
IF 1.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-08 DOI: 10.4274/jcrpe.galenos.2024.2024-3-14
Esther M G Bormans, Janneke H M Schuurs-Hoeijmakers, Petra van Setten, Linda A J Hendricks, Meggie M C M Drissen, Martin Gotthardt, Hedi L Claahsen-van der Grinten, Nicoline Hoogerbrugge, Jolanda H Schieving

Objective: Children with PTEN hamartoma tumor syndrome (PHTS) are at increased risk for developing thyroid abnormalities, including differentiated thyroid carcinoma (DTC). The Dutch PHTS guideline recommends ultrasound surveillance starting from age 18. Since the literature describes PHTS patients who developed DTC before age 18, the Dutch PHTS expertise centre has initiated annual ultrasound surveillance starting from age 12. The purpose of this study was to identify the yield of thyroid ultrasound surveillance in children.

Methods: A retrospective single centre cohort study was conducted. Pediatric PHTS patients who received thyroid ultrasound surveillance before age 18 between 2016-2023 were included. Patients' medical records have been reviewed. Primary outcomes included prevalence and time to develop thyroid nodules ≥10mm, nodular growth, goiter, thyroiditis and DTC. Descriptive statistics and Kaplan-Meier analyses were performed.

Results: Forty-three patients were included. Two patients (5%) were diagnosed with DTC at ages 12 and 17. Both DTCs were identified as minimally invasive follicular carcinoma at stages pT3NxMx and pT1NxMx respectively. A total of 84% were diagnosed with thyroid abnormalities at a median age of 12 years (range 9-18). Most common findings were benign, including nodular disease (74%), goiter (30%) and autoimmune thyroiditis (12%). Nodular growth was observed in 14 patients (33%) resulting in (hemi)thyroidectomy in 7 patients (16%).

Conclusion: Thyroid ultrasound surveillance resulted in the detection of DTC in 2/43 PHTS patients before age 18. These findings support the recommendation to initiate thyroid ultrasound surveillance in children at least from age 12, preferably within an expertise centre.

目的患有 PTEN 仓瘤综合征(PHTS)的儿童罹患甲状腺异常(包括分化型甲状腺癌(DTC))的风险较高。荷兰PHTS指南建议从18岁开始进行超声监测。由于文献中描述的PHTS患者在18岁之前就已发展为DTC,荷兰PHTS专业中心已开始从12岁起每年进行一次超声监测。本研究旨在确定儿童甲状腺超声监测的效果:方法:进行了一项单中心队列回顾性研究。研究纳入了2016-2023年间18岁前接受甲状腺超声监测的儿童PHTS患者。研究人员查阅了患者的病历。主要结果包括甲状腺结节≥10毫米、结节生长、甲状腺肿、甲状腺炎和DTC的发病率和发病时间。对结果进行了描述性统计和 Kaplan-Meier 分析:结果:共纳入 43 例患者。两名患者(5%)分别在 12 岁和 17 岁时被诊断出患有 DTC。两例 DTC 均被确定为微小浸润性滤泡癌,分别为 pT3NxMx 期和 pT1NxMx 期。共有84%的患者在12岁(9-18岁不等)时被诊断出甲状腺异常。最常见的检查结果是良性的,包括结节病(74%)、甲状腺肿(30%)和自身免疫性甲状腺炎(12%)。14名患者(33%)出现结节性增生,7名患者(16%)因此接受了(半)甲状腺切除术:甲状腺超声监测结果显示,2/43 的 PHTS 患者在 18 岁前发现了 DTC。这些研究结果支持至少从12岁开始对儿童进行甲状腺超声监测的建议,最好在专业中心进行。
{"title":"Experience in a PHTS Expertise Centre: Yield of Thyroid Ultrasound Surveillance in Children with PTEN Hamartoma Tumor Syndrome.","authors":"Esther M G Bormans, Janneke H M Schuurs-Hoeijmakers, Petra van Setten, Linda A J Hendricks, Meggie M C M Drissen, Martin Gotthardt, Hedi L Claahsen-van der Grinten, Nicoline Hoogerbrugge, Jolanda H Schieving","doi":"10.4274/jcrpe.galenos.2024.2024-3-14","DOIUrl":"https://doi.org/10.4274/jcrpe.galenos.2024.2024-3-14","url":null,"abstract":"<p><strong>Objective: </strong>Children with PTEN hamartoma tumor syndrome (PHTS) are at increased risk for developing thyroid abnormalities, including differentiated thyroid carcinoma (DTC). The Dutch PHTS guideline recommends ultrasound surveillance starting from age 18. Since the literature describes PHTS patients who developed DTC before age 18, the Dutch PHTS expertise centre has initiated annual ultrasound surveillance starting from age 12. The purpose of this study was to identify the yield of thyroid ultrasound surveillance in children.</p><p><strong>Methods: </strong>A retrospective single centre cohort study was conducted. Pediatric PHTS patients who received thyroid ultrasound surveillance before age 18 between 2016-2023 were included. Patients' medical records have been reviewed. Primary outcomes included prevalence and time to develop thyroid nodules ≥10mm, nodular growth, goiter, thyroiditis and DTC. Descriptive statistics and Kaplan-Meier analyses were performed.</p><p><strong>Results: </strong>Forty-three patients were included. Two patients (5%) were diagnosed with DTC at ages 12 and 17. Both DTCs were identified as minimally invasive follicular carcinoma at stages pT3NxMx and pT1NxMx respectively. A total of 84% were diagnosed with thyroid abnormalities at a median age of 12 years (range 9-18). Most common findings were benign, including nodular disease (74%), goiter (30%) and autoimmune thyroiditis (12%). Nodular growth was observed in 14 patients (33%) resulting in (hemi)thyroidectomy in 7 patients (16%).</p><p><strong>Conclusion: </strong>Thyroid ultrasound surveillance resulted in the detection of DTC in 2/43 PHTS patients before age 18. These findings support the recommendation to initiate thyroid ultrasound surveillance in children at least from age 12, preferably within an expertise centre.</p>","PeriodicalId":48805,"journal":{"name":"Journal of Clinical Research in Pediatric Endocrinology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autosomal Recessive Hypophosphatemic Rickets Type 2 Associated with a Novel ENPP1 Variant in a Taiwanese Girl. 一名台湾女孩的常染色体隐性低磷血症 2 型佝偻病与新型 ENPP1 变异有关
IF 1.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-16 DOI: 10.4274/jcrpe.galenos.2024.2024-3-8
Han-Yi Lin, Ni-Chung Lee, Meng-Ju Melody Tsai, Ting-Ming Wang, Yi-Ching Tung

Autosomal recessive hypophosphatemic rickets (HR) type 2 (ARHR2) is a rare form of HR caused by variant of the gene encoding ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). Our patient presented with a history of unsteady gait and progressively bowing legs that had commenced at the age of 1 year. Laboratory tests revealed an elevated level of fibroblast growth factor 23 (FGF23), hypophosphatemia, and a high urine phosphate level. Radiography revealed the typical features of rickets. Next-generation sequencing identified a previously reported c.783C>G (p.Tyr261Ter) and a novel c.1092-42A>G variant in the ENPP1 gene. The patient was prescribed oral phosphates and active vitamin D and underwent guided growth of both distal femora and proximal tibiae commencing at the age of 3 years. No evidence of generalized arterial calcification was apparent during follow-up, and growth rate was satisfactory.

常染色体隐性低磷酸盐性佝偻病(HR)2型(ARHR2)是一种罕见的HR,由编码外核苷酸焦磷酸酶/磷酸二酯酶1(ENPP1)的基因变异引起。患者一岁时开始出现步态不稳和双腿逐渐弓起的症状。实验室检查显示成纤维细胞生长因子23(FGF23)水平升高、低磷血症和尿磷酸盐水平升高。影像学检查显示了佝偻病的典型特征。下一代测序确定了先前报告的 c.783C>G(p.Tyr261Ter)和 ENPP1 基因中的新型 c.1092-42A>G 变异。患者接受了口服磷酸盐和活性维生素 D 的治疗,并在 3 岁时开始接受股骨远端和胫骨近端的引导生长治疗。随访期间未发现全身动脉钙化的迹象,生长速度令人满意。
{"title":"Autosomal Recessive Hypophosphatemic Rickets Type 2 Associated with a Novel <i>ENPP1</i> Variant in a Taiwanese Girl.","authors":"Han-Yi Lin, Ni-Chung Lee, Meng-Ju Melody Tsai, Ting-Ming Wang, Yi-Ching Tung","doi":"10.4274/jcrpe.galenos.2024.2024-3-8","DOIUrl":"https://doi.org/10.4274/jcrpe.galenos.2024.2024-3-8","url":null,"abstract":"<p><p>Autosomal recessive hypophosphatemic rickets (HR) type 2 (ARHR2) is a rare form of HR caused by variant of the gene encoding ectonucleotide pyrophosphatase/phosphodiesterase 1 (<i>ENPP1</i>). Our patient presented with a history of unsteady gait and progressively bowing legs that had commenced at the age of 1 year. Laboratory tests revealed an elevated level of fibroblast growth factor 23 (FGF23), hypophosphatemia, and a high urine phosphate level. Radiography revealed the typical features of rickets. Next-generation sequencing identified a previously reported c.783C>G (p.Tyr261Ter) and a novel c.1092-42A>G variant in the <i>ENPP1</i> gene. The patient was prescribed oral phosphates and active vitamin D and underwent guided growth of both distal femora and proximal tibiae commencing at the age of 3 years. No evidence of generalized arterial calcification was apparent during follow-up, and growth rate was satisfactory.</p>","PeriodicalId":48805,"journal":{"name":"Journal of Clinical Research in Pediatric Endocrinology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hereditary Severe Insulin-resistance Syndrome and Acanthosis Nigricans Caused by Novel Mutations in the INSR Gene. 由 INSR 基因新型突变引起的遗传性严重胰岛素抵抗综合征和黑棘皮病
IF 1.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-02 DOI: 10.4274/jcrpe.galenos.2024.2024-2-14
Chen Chongyang, Zhao Yangting, Li Kai, Lv Xiaoyu, Wang Yawen, Zhen Donghu, Fu Songbo, Ma Lihua, Zhou Liyuan, Liu Jingfang

Most cases associated with Hereditary Severe Insulin Resistance Syndrome (H-SIRS) are linked to mutations in the insulin receptor (INSR) gene. Patients with H-SIRS typically manifest symptoms of hyperinsulinemia, insulin resistance, and diabetes mellitus. Other symptoms include impaired glucose regulation, hyperandrogenism, and the presence of acanthosis nigricans (AN). In this report, we present two cases of H-SIRS in female children exhibiting various symptoms, such as hyperinsulinemia, fasting hypoglycemia, postprandial hyperglycemia, overweight, fatty liver, hyperandrogenism, and varying degrees of AN. One patient also presented with mental retardation. Gene sequencing identified specific mutations in the INSR gene for both patients: c.2663A > G (p.Tyr888Cys) and c.38_61del (p.Pro13_Ala20del). These mutations have the potential to disrupt the interaction between INSR and insulin, leading to abnormal insulin signaling, insulin resistance, and various clinical manifestations.

大多数与遗传性严重胰岛素抵抗综合征(H-SIRS)相关的病例都与胰岛素受体(INSR)基因突变有关。H-SIRS 患者通常表现为高胰岛素血症、胰岛素抵抗和糖尿病。其他症状还包括葡萄糖调节功能受损、高雄激素症和黑棘皮症(AN)。在本报告中,我们介绍了两例女性 H-SIRS 患儿,她们表现出各种症状,如高胰岛素血症、空腹低血糖、餐后高血糖、超重、脂肪肝、高雄激素症和不同程度的黑棘皮症。其中一名患者还伴有智力低下。基因测序发现这两名患者的 INSR 基因都存在特定突变:c.2663A > G(p.Tyr888Cys)和 c.38_61del(p.Pro13_Ala20del)。这些突变可能会破坏 INSR 与胰岛素之间的相互作用,导致胰岛素信号异常、胰岛素抵抗和各种临床表现。
{"title":"Hereditary Severe Insulin-resistance Syndrome and Acanthosis Nigricans Caused by Novel Mutations in the <i>INSR</i> Gene.","authors":"Chen Chongyang, Zhao Yangting, Li Kai, Lv Xiaoyu, Wang Yawen, Zhen Donghu, Fu Songbo, Ma Lihua, Zhou Liyuan, Liu Jingfang","doi":"10.4274/jcrpe.galenos.2024.2024-2-14","DOIUrl":"https://doi.org/10.4274/jcrpe.galenos.2024.2024-2-14","url":null,"abstract":"<p><p>Most cases associated with Hereditary Severe Insulin Resistance Syndrome (H-SIRS) are linked to mutations in the insulin receptor (<i>INSR</i>) gene. Patients with H-SIRS typically manifest symptoms of hyperinsulinemia, insulin resistance, and diabetes mellitus. Other symptoms include impaired glucose regulation, hyperandrogenism, and the presence of acanthosis nigricans (AN). In this report, we present two cases of H-SIRS in female children exhibiting various symptoms, such as hyperinsulinemia, fasting hypoglycemia, postprandial hyperglycemia, overweight, fatty liver, hyperandrogenism, and varying degrees of AN. One patient also presented with mental retardation. Gene sequencing identified specific mutations in the <i>INSR</i> gene for both patients: c.2663A > G (p.Tyr888Cys) and c.38_61del (p.Pro13_Ala20del). These mutations have the potential to disrupt the interaction between <i>INSR</i> and insulin, leading to abnormal insulin signaling, insulin resistance, and various clinical manifestations.</p>","PeriodicalId":48805,"journal":{"name":"Journal of Clinical Research in Pediatric Endocrinology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inequalities in Access to Diabetes Technologies in Children with Type 1 Diabetes: A Multicenter, Cross-sectional Study from Türkiye. 1 型糖尿病儿童在获得糖尿病技术方面的不平等:土耳其多中心横断面研究。
IF 1.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-02 DOI: 10.4274/jcrpe.galenos.2024.2024-4-6
Kagan Ege Karakus, Sibel Sakarya, Ruken Yıldırım, Şervan Özalkak, Mehmet N Özbek, Nurdan Yıldırım, Gülcan Delibağ, Beray S Eklioğlu, Belma Haliloğlu, Murat Aydın, Heves Kırmızıbekmez, Tuğba Gökçe, Ecem Can, Elif Eviz, Gül Yeşiltepe-Mutlu, Şükrü Hatun

Objective: To determine inequalities in access to diabetes technologies and the effect of socioeconomic factors on families with children with type 1 diabetes.

Methods: In this multicenter cross-sectional study, parents of children with type 1 diabetes completed a questionnaire about household sociodemographic characteristics, latest HbA1c values, continuous glucose monitoring (CGM) and insulin pump use of children, the education and working status of parents. These characteristics were compared between technology use (only-CGM, only-pump, CGM+pump, no technology use).

Results: Among 882 families, only-CGM users, only-pump users, and CGM+pump users compared with no technology users, adjusting for age, sex, region, education levels, number of working parents, and household income. Children living in the least developed region had lower odds of having only-CGM (OR=0.20, 95%CI 0.12-0.34) and having CGM+pump (OR=0.07, 95%CI 0.03-0.22) compared with those living in the most developed region. Children with parents who had not finished high school had lower odds of having only-CGM (Mothers: OR=0.36, 95%CI 0.19-0.66; fathers: OR=0.32, 95%CI 0.18-0.60) or both CGM+pump (OR=0.27, 95%CI 0.11-0.64; fathers: OR=0.34, 95%CI 0.15-0.79) rather than no-technology compared to children whose parents has a university degree. Every $840 increase in the household income increased the odds by 5% for having only-CGM (OR=1.05, 95%CI 1.02-1.09) and CGM+pump (OR=1.05, 95%CI 1.01-1.08).

Conclusion: Socioeconomic factors such as education, regions, and income were associated with inequality in access to technologies. The inequalities are more prominent in access to CGM while CGM had a bigger contribution to glycemic control.

目的确定 1 型糖尿病患儿家庭在获得糖尿病技术方面的不平等以及社会经济因素的影响:在这项多中心横断面研究中,1 型糖尿病患儿的父母填写了一份调查问卷,内容包括家庭社会人口特征、最新 HbA1c 值、患儿连续血糖监测 (CGM) 和胰岛素泵的使用情况、父母的教育和工作状况。将这些特征与技术使用情况(仅使用 CGM、仅使用胰岛素泵、CGM+胰岛素泵、未使用技术)进行了比较:在 882 个家庭中,只使用 CGM、只使用泵和 CGM+ 泵的家庭与不使用技术的家庭进行了比较,并对年龄、性别、地区、教育水平、工作父母人数和家庭收入进行了调整。与生活在最发达地区的儿童相比,生活在最不发达地区的儿童只使用 CGM(OR=0.20,95%CI 0.12-0.34)和使用 CGM+ 泵(OR=0.07,95%CI 0.03-0.22)的几率较低。与父母拥有大学学历的儿童相比,父母未完成高中学业的儿童仅拥有 CGM(母亲:OR=0.36,95%CI 0.19-0.66;父亲:OR=0.32,95%CI 0.18-0.60)或同时拥有 CGM+泵(OR=0.27,95%CI 0.11-0.64;父亲:OR=0.34,95%CI 0.15-0.79)而非无技术的几率较低。家庭收入每增加 840 美元,仅使用 CGM(OR=1.05,95%CI 1.02-1.09)和 CGM+ 泵(OR=1.05,95%CI 1.01-1.08)的几率就会增加 5%:结论:教育、地区和收入等社会经济因素与获得技术方面的不平等有关。结论:教育、地区和收入等社会经济因素与获得技术方面的不平等有关,在获得 CGM 方面的不平等更为突出,而 CGM 对血糖控制的贡献更大。
{"title":"Inequalities in Access to Diabetes Technologies in Children with Type 1 Diabetes: A Multicenter, Cross-sectional Study from Türkiye.","authors":"Kagan Ege Karakus, Sibel Sakarya, Ruken Yıldırım, Şervan Özalkak, Mehmet N Özbek, Nurdan Yıldırım, Gülcan Delibağ, Beray S Eklioğlu, Belma Haliloğlu, Murat Aydın, Heves Kırmızıbekmez, Tuğba Gökçe, Ecem Can, Elif Eviz, Gül Yeşiltepe-Mutlu, Şükrü Hatun","doi":"10.4274/jcrpe.galenos.2024.2024-4-6","DOIUrl":"https://doi.org/10.4274/jcrpe.galenos.2024.2024-4-6","url":null,"abstract":"<p><strong>Objective: </strong>To determine inequalities in access to diabetes technologies and the effect of socioeconomic factors on families with children with type 1 diabetes.</p><p><strong>Methods: </strong>In this multicenter cross-sectional study, parents of children with type 1 diabetes completed a questionnaire about household sociodemographic characteristics, latest HbA1c values, continuous glucose monitoring (CGM) and insulin pump use of children, the education and working status of parents. These characteristics were compared between technology use (only-CGM, only-pump, CGM+pump, no technology use).</p><p><strong>Results: </strong>Among 882 families, only-CGM users, only-pump users, and CGM+pump users compared with no technology users, adjusting for age, sex, region, education levels, number of working parents, and household income. Children living in the least developed region had lower odds of having only-CGM (OR=0.20, 95%CI 0.12-0.34) and having CGM+pump (OR=0.07, 95%CI 0.03-0.22) compared with those living in the most developed region. Children with parents who had not finished high school had lower odds of having only-CGM (Mothers: OR=0.36, 95%CI 0.19-0.66; fathers: OR=0.32, 95%CI 0.18-0.60) or both CGM+pump (OR=0.27, 95%CI 0.11-0.64; fathers: OR=0.34, 95%CI 0.15-0.79) rather than no-technology compared to children whose parents has a university degree. Every $840 increase in the household income increased the odds by 5% for having only-CGM (OR=1.05, 95%CI 1.02-1.09) and CGM+pump (OR=1.05, 95%CI 1.01-1.08).</p><p><strong>Conclusion: </strong>Socioeconomic factors such as education, regions, and income were associated with inequality in access to technologies. The inequalities are more prominent in access to CGM while CGM had a bigger contribution to glycemic control.</p>","PeriodicalId":48805,"journal":{"name":"Journal of Clinical Research in Pediatric Endocrinology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141493996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of the Admission and Follow-up Characteristics of Children Diagnosed with Secondary Osteoporosis. 评估被诊断为继发性骨质疏松症的儿童的入院和随访特征。
IF 1.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-02 DOI: 10.4274/jcrpe.galenos.2024.2024-4-4
Emine Kübra Şen, Merih Berberoğlu, Gizem Şenyazar, Sirmen Kızılcan Çetin, Ayşegül Ceran, Seda Erişen Karaca, Elif Özsu, Zehra Aycan, Zeynep Şıklar
<p><strong>Objective: </strong>Secondary osteoporosis is a condition when the underlying disease or its treatment causes the bone mass to decrease and the bone structure to deteriorate, increasing the risk of fracture. The importance of diagnosis and treatment during childhood and adolescence is due to its long-term negative effects. In this study, our objectives were to determine the diagnostic findings, treatment efficacy, and follow-up characteristics of childhood with secondary osteoporosis.</p><p><strong>Methods: </strong>61 patients diagnosed with secondary osteoporosis between January 2000 and January 2021 were included in the study. The research is a cross-sectional and descriptive study. Study participants had to be under 18 years of age when the primary underlying disease was diagnosed and received treatment for secondary osteoporosis. Patient data were collected from patient files. Patient data were obtained from patient files in hospitals and were interpreted through the IBM SPSS Statistics for Windows version 20.0 (IBM Corp, Armonk, NY, USA).</p><p><strong>Results: </strong>61 patients (28 women/33 men) were evaluated. The most common underlying primary diseases in patients with secondary osteoporosis were inflammatory diseases (57.7%), neuromuscular diseases (26.2%), immunodeficiency (13.1%), acute lymphoblastic leukemia (8.2%), metabolic diseases (8.2%), and solid organ transplantation. (8.2%), bone marrow transplantation (6.6%) and epilepsy (6.6%). The average chronological age when secondary osteoporosis was diagnosed was 11.89±4.88 years. They were evaluated for osteoporosis 6.39±5.13 years after the onset of the underlying primary chronic diseases. 78.7% of the patients had one or more chronic drug use. Systemic steroid use was 59%, chemotherapeutics 23%, immunomodulatory drugs 19.7%, antiepileptic drugs 8.2%, inhaled steroids 4.9%, IVIG 1.6%, and antituberculosis drugs 1.6%. Additionally, 1.6% of the patients were using testosterone as replacement, 3.3% L-Thyroxine, 1.6% estrogen, and 1.6% growth hormone. Bone pain was detected in 49.2% of the patients. All patients had vertebral fractures before treatment. Bisphosphonate treatment was given to 45 patients with secondary osteoporosis. There was a statistically significant increase in mean bone mineral density (BMD) and bone mineral content values six months after treatment, (p<0.001). There was a significant increase in BMD Z-score values for chronological and height age (p<0.001). The patients' BMD values increased on average by 31.15% with treatment. Following bisphosphonate treatment, there was a significant reduction in both fracture number and bone pain in patients (p<0.01). When patients who received and did not receive steroid treatment were compared, both groups received similar benefits from bisphosphonate treatment.</p><p><strong>Conclusion: </strong>Secondary osteoporosis is a condition that is influenced by many factors, such as the primary disease causing osteopor
目的:继发性骨质疏松症是指由于潜在疾病或治疗导致骨量减少和骨结构退化,从而增加骨折风险的一种病症。由于其长期的负面影响,在儿童和青少年时期进行诊断和治疗非常重要。在这项研究中,我们的目标是确定儿童继发性骨质疏松症患者的诊断结果、治疗效果和随访特点。方法:研究纳入了 2000 年 1 月至 2021 年 1 月期间诊断为继发性骨质疏松症的 61 例患者。研究为横断面描述性研究。研究参与者在确诊原发性基础疾病时必须未满 18 岁,并接受过继发性骨质疏松症的治疗。患者数据来自患者档案。患者数据来自医院的患者档案,并通过 IBM SPSS Statistics for Windows 20.0 版(IBM Corp, Armonk, NY, USA)进行解释:对 61 名患者(28 名女性/33 名男性)进行了评估。继发性骨质疏松症患者最常见的原发性基础疾病是炎症性疾病(57.7%)、神经肌肉疾病(26.2%)、免疫缺陷(13.1%)、急性淋巴细胞白血病(8.2%)、代谢性疾病(8.2%)和实体器官移植。(骨质疏松症(8.2%)、骨髓移植(6.6%)和癫痫(6.6%)。被诊断为继发性骨质疏松症的平均年龄为(11.89±4.88)岁。他们是在原发性慢性疾病发病 6.39±5.13 年后接受骨质疏松症评估的。78.7%的患者长期服用一种或多种药物。全身使用类固醇药物的占 59%,化疗药物占 23%,免疫调节药物占 19.7%,抗癫痫药物占 8.2%,吸入类固醇药物占 4.9%,IVIG 占 1.6%,抗结核药物占 1.6%。此外,1.6%的患者使用睾酮作为替代药物,3.3%使用左旋甲状腺素,1.6%使用雌激素,1.6%使用生长激素。49.2%的患者出现骨痛。所有患者在治疗前均有脊椎骨折。45 名继发性骨质疏松症患者接受了双膦酸盐治疗。治疗 6 个月后,平均骨矿物质密度(BMD)和骨矿物质含量值有了统计学意义上的明显增加(p):继发性骨质疏松症是一种受多种因素影响的疾病,如导致骨质疏松症的原发性疾病、长期用药,尤其是类固醇。如果不及时治疗,骨质疏松症会导致骨痛、骨折、不能活动、骨骼线性生长减少等重要疾病。当用于治疗儿童继发性骨质疏松症时,双膦酸盐可显著改善 BMD,降低骨折风险。
{"title":"Assessment of the Admission and Follow-up Characteristics of Children Diagnosed with Secondary Osteoporosis.","authors":"Emine Kübra Şen, Merih Berberoğlu, Gizem Şenyazar, Sirmen Kızılcan Çetin, Ayşegül Ceran, Seda Erişen Karaca, Elif Özsu, Zehra Aycan, Zeynep Şıklar","doi":"10.4274/jcrpe.galenos.2024.2024-4-4","DOIUrl":"https://doi.org/10.4274/jcrpe.galenos.2024.2024-4-4","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Secondary osteoporosis is a condition when the underlying disease or its treatment causes the bone mass to decrease and the bone structure to deteriorate, increasing the risk of fracture. The importance of diagnosis and treatment during childhood and adolescence is due to its long-term negative effects. In this study, our objectives were to determine the diagnostic findings, treatment efficacy, and follow-up characteristics of childhood with secondary osteoporosis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;61 patients diagnosed with secondary osteoporosis between January 2000 and January 2021 were included in the study. The research is a cross-sectional and descriptive study. Study participants had to be under 18 years of age when the primary underlying disease was diagnosed and received treatment for secondary osteoporosis. Patient data were collected from patient files. Patient data were obtained from patient files in hospitals and were interpreted through the IBM SPSS Statistics for Windows version 20.0 (IBM Corp, Armonk, NY, USA).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;61 patients (28 women/33 men) were evaluated. The most common underlying primary diseases in patients with secondary osteoporosis were inflammatory diseases (57.7%), neuromuscular diseases (26.2%), immunodeficiency (13.1%), acute lymphoblastic leukemia (8.2%), metabolic diseases (8.2%), and solid organ transplantation. (8.2%), bone marrow transplantation (6.6%) and epilepsy (6.6%). The average chronological age when secondary osteoporosis was diagnosed was 11.89±4.88 years. They were evaluated for osteoporosis 6.39±5.13 years after the onset of the underlying primary chronic diseases. 78.7% of the patients had one or more chronic drug use. Systemic steroid use was 59%, chemotherapeutics 23%, immunomodulatory drugs 19.7%, antiepileptic drugs 8.2%, inhaled steroids 4.9%, IVIG 1.6%, and antituberculosis drugs 1.6%. Additionally, 1.6% of the patients were using testosterone as replacement, 3.3% L-Thyroxine, 1.6% estrogen, and 1.6% growth hormone. Bone pain was detected in 49.2% of the patients. All patients had vertebral fractures before treatment. Bisphosphonate treatment was given to 45 patients with secondary osteoporosis. There was a statistically significant increase in mean bone mineral density (BMD) and bone mineral content values six months after treatment, (p&lt;0.001). There was a significant increase in BMD Z-score values for chronological and height age (p&lt;0.001). The patients' BMD values increased on average by 31.15% with treatment. Following bisphosphonate treatment, there was a significant reduction in both fracture number and bone pain in patients (p&lt;0.01). When patients who received and did not receive steroid treatment were compared, both groups received similar benefits from bisphosphonate treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Secondary osteoporosis is a condition that is influenced by many factors, such as the primary disease causing osteopor","PeriodicalId":48805,"journal":{"name":"Journal of Clinical Research in Pediatric Endocrinology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141493995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Research in Pediatric Endocrinology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1